Details for Patent: 12,629,404
✉ Email this page to a colleague
Which drugs does patent 12,629,404 protect, and when does it expire?
Patent 12,629,404 protects MOUNJARO, MOUNJARO (AUTOINJECTOR), ZEPBOUND, and ZEPBOUND (AUTOINJECTOR), and is included in two NDAs.
This patent has fifty-four patent family members in thirty-four countries.
Drugs Protected by US Patent 12,629,404
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-007 | Jul 28, 2023 | RX | Yes | Yes | 12,629,404 | ⤷ Start Trial | Y | A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE | ⤷ Start Trial | |||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-007 | Jul 28, 2023 | RX | Yes | Yes | 12,629,404 | ⤷ Start Trial | Y | A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE | ⤷ Start Trial | |||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-008 | Jul 28, 2023 | RX | Yes | Yes | 12,629,404 | ⤷ Start Trial | Y | A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE | ⤷ Start Trial | |||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-008 | Jul 28, 2023 | RX | Yes | Yes | 12,629,404 | ⤷ Start Trial | Y | A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE | ⤷ Start Trial | |||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-009 | Jul 28, 2023 | RX | Yes | Yes | 12,629,404 | ⤷ Start Trial | Y | A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE | ⤷ Start Trial | |||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-009 | Jul 28, 2023 | RX | Yes | Yes | 12,629,404 | ⤷ Start Trial | Y | A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE | ⤷ Start Trial | |||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-010 | Jul 28, 2023 | RX | Yes | Yes | 12,629,404 | ⤷ Start Trial | Y | A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,629,404
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 115542 | ⤷ Start Trial | |||
| Australia | 2019289110 | ⤷ Start Trial | |||
| Australia | 2022279524 | ⤷ Start Trial | |||
| Australia | 2024266715 | ⤷ Start Trial | |||
| Brazil | 112020023452 | ⤷ Start Trial | |||
| Canada | 3103469 | ⤷ Start Trial | |||
| Chile | 2020003359 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
